NCT00669994已完成4 期
Prospective, Open Label Non-comparative, Multi-center Trial to Evaluate the Efficacy and Safety of Cipro® XR 500 mg Once Daily for 3 Days in Treating Female Patients With Acute, Uncomplicated, Symptomatic Lower Urinary Tract Infections
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 180
- 主要终点
- Bacteriologic outcome in patients with UTI caused by S. saprophyticus
研究概览
简要总结
This trial evaluated how effective and safe Cipro XR was in treating female patients with signs and symptoms of a lower urinary tract infections. After 3 days of treatment, patients were evaluated to determine if signs/symptoms disappeared and the infecting bacteria was eliminated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 44 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Non-pregnant, non-lactating female outpatients between the ages of 18 - 44 years (inclusive)
- •Patients with at least two of the following clinical signs and symptoms of an uUTI:
- •Frequency
- •Suprapubic pain
- •Patients with onset of symptoms < 72 hours prior to study entry
- •Patients with one positive pre-treatment clean-catch midstream urine culture at enrollment in the study, defined as > 10000 CFU/mL (study drug treatment is permitted prior to the availability of urine culture results)
- •Positive leukocyte esterase (LE) (1+ or greater) utilizing a urine dipstick method of analysis
- •Patients willing to give written informed consent
- •Cultures must be performed on pre-treatment clean-catch midstream urine (MSU) specimens
排除标准
- •Women who are pregnant, nursing, or not using two medically accepted, effective methods of birth control
- •Patients with known or suspected hypersensitivity to quinolones
- •Patients unable to take oral medication for any reason
- •Patients with an asymptomatic bacteriuria
- •Patients with complicated UTI, defined as: a clinical syndrome characterized by the development of systemic and local signs and symptoms of fever (> 38.3°C/101°F orally), chills, malaise, flank pain, back pain, or costovertebral angle (CVA) pain or tenderness
- •Symptoms as outlined in the inclusion criteria occurring in the presence of a functional or anatomical abnormality of the urinary tract or in the presence of urinary catheterization
- •Patients with symptoms of a UTI within the 4 weeks prior to the present episode
- •Patients with the onset of symptoms >72 hours prior to study entry
- •Patients with three or more episodes of any UTI in the past 12 months
- •Patients with evidence of factors predisposing to the development of UTIs, including calculi, stricture, primary renal disease (e.g. polycystic renal disease), or neurogenic bladder
- •Patients who received systemic antimicrobial therapy within 48 hours prior to entry
- •Patients with a neutrophil count < 1000/mm3, CD4 < 200/mm3 or other conditions associated with significant depression in host defense; HIV testing is not mandatory
- •Patients requiring concomitant systemic antibacterial therapy with agents not specified in this protocol
- •Patients with a previous history of tendinopathy associated with fluoroquinolones
- •Patients diagnosed with a rapidly fatal underlying disease (death expected within six months)
- •Patients requiring concomitant use of theophylline
- •Patients previously enrolled in this clinical study
- •Patients taking an investigational drug in the last 30 days
研究组 & 干预措施
Arm 1
Experimental
干预措施: Ciprofloxacin (Drug)
结局指标
主要结局
Bacteriologic outcome in patients with UTI caused by S. saprophyticus
时间窗: 4-11 days post-treatment
次要结局
- Adverse Events Collection(Up to 4-11 days post-treatment)
- Clinical Response(4-11 days post-treatment)
- Incidence of premature terminations(Premature discontinuation)
研究者
相似试验
已完成
4 期
Study To Evaluate The Efficacy And Safety Of Ciprofloxacin Extended-Release (Cipro® XR) 1000 mg Tablets Given Once Daily For 7 To 14 Days In The Treatment Of Patients 18 Years Or Older With Complicated Urinary Tract Infections Caused By Pseudomonas Aeruginosa And Other Common UropathogensUrinary Tract InfectionsNCT00481689Bayer500
已完成
4 期
Cipro® XR in Therapeutic Response and Activity (eXtRa) - Assessing Symptom Relief in Urinary Tract InfectionsUrinary Tract InfectionNCT00676533Bayer276
已完成
4 期
A Phase IV Study of Cipro XR in Uncomplicated UTIUrinary Tract InfectionsNCT00663806Bayer7,614
已完成
3 期
Efficacy and Safety of CIPRO XR Versus CIPRO IR in Patients With Complicated Urinary Tract InfectionsUrinary Tract InfectionNCT00668122Bayer212
已完成
2 期
A Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Investigate the Efficacy, Safety and Duration of Effect of a Single Administration of Various Doses of Cetrorelix SR in Subjects With Histologically Confirmed EndometriosisEndometriosisNCT00244452Solvay Pharmaceuticals